Risk Factors for PONV in Patients Undergoing Hysteroscopic Surgery

July 26, 2024 updated by: Jiang Liu, Weifang Medical University

Risk Factors for Postoperative Nausea and Vomiting in Patients Undergoing Day-case Hysteroscopic Surgery

The purpose of this study was to construct and validate a risk prediction model for PONV in patients undergoing hysteroscopic day-case surgery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study predicted the risk of postoperative nausea and vomiting in patients undergoing day-case hysteroscopic surgery by constructing and validating a web-based dynamic nomogram.

Study Type

Observational

Enrollment (Actual)

1583

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shandong
      • Weifang, Shandong, China, 265100
        • Weifang People's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Female patients undergoing gynaecological hysteroscopic day-case surgery.

Description

Inclusion Criteria:

  • Female patients undergoing hysteroscopic day-case surgery and aged 18 years.

Exclusion Criteria:

  • Patients with intraoperative change of surgical method and unstable postoperative vital signs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Observation group
The patient experience the postoperative nausea or vomiting
Other: The presence of nausea and vomiting within 24 hours after surgery
This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
Control group
The patient did not experience postoperative nausea or vomiting
Other: Non-existence of nausea and vomiting within 24 hours after surgery
This is a prospective risk prediction model building, thus there is no traditional definition of intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PONV
Time Frame: Within 24 hours after surgery
The occurrence and severity of PONV is evaluated by Visual Analogue Scale (VAS). The VAS scale ranges from 0 to 10, with larger scores meaning that the patient has more severe PONV.
Within 24 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Weifang Medical University

Investigators

  • Study Director: Shirong Fang, Researcher, Weifang People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Actual)

January 1, 2024

Study Completion (Actual)

June 1, 2024

Study Registration Dates

First Submitted

July 22, 2024

First Submitted That Met QC Criteria

July 26, 2024

First Posted (Actual)

July 29, 2024

Study Record Updates

Last Update Posted (Actual)

July 29, 2024

Last Update Submitted That Met QC Criteria

July 26, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KYLL20230217-3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Complications

Clinical Trials on The presence of nausea and vomiting within 24 hours after surgery

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe